Chris Markoch

Chris Markoch

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Get Ready for the Rally on Advanced Micro Devices

With new gaming consoles and the likely continuation of remote work and learning, AMD stock has enought catalysts to overcome its high valuation.

Callon Petroleum Is a Fairy Tale Coming to an End

Investors seem to love the action they're getting from oil stocks, like CPE stock, that are flirting with bankruptcy. But it's time to walk away.

Can Nokia Stock Avoid Paying the China Price?

Just as 5G looked like it was going to catapult NOK stock higher, rising global tensions with China may squelch the rally before it starts.

OK Boomer, Flexion Stock Is Made For You

FLXN stock has been falling because the company is not in the race for a Covid-19 vaccine. But as that field narrows, FLX is worth a look.

Do You Really Want to Be Part of the 3% That Own Shares in Whiting Petroleum?

As Whiting Petroleum prepares to exit bankruptcy proceedings, investors will learn what the new valuation is for WLL stock. Hint, it doesn't look good.

The 5 Best Telehealth Stocks on the Market Right Now

The pandemic is accelerating the need for virtual healthcare, and these five telehealth stocks are a great way to benefit.

The Curtain Is Coming Down on Inovio Pharmaceuticals’ Vaccine Candidate

As multiple companies advance vaccine candidates into late-stage clinical trials, INO stock is losing momentum. Is this the end or just a pause?

Buy Zynga Stock Now Because History Favors the Bold

Zynga is benefitting from a pandemic-driven surge in video game interest, but a new acquisition is the real reason to buy Zynga stock.

It’s About That Time for Electronic Arts

The upcoming release of Madden 21 may be the best reason investors have to believe EA stock will continue to grow. But it's not the only reason.

Lyft Faces Long Odds to Growth as Its Market Is Likely to Shrink

Lyft is doing all the right things to ensure it survives the pandemic. But a shrinking audience for ride-hailing services makes Lyft stock a poor bet.